Alcidion Group Limited · ASX:ALC
Alcidion — Canaccord Genuity 43rd Annual Growth Conference 2023
20 slides from Alcidion's conference presentation, Aug 10, 2023
Slide 1: Canaccord Annual Growth Conference Presentation (ASX release)
10 August 2023 Australian Securities Exchange 20 Bridge Street Sydney NSW 2000 Canaccord Annual Growth Conference Presentation Melbourne, Victoria: Alcidion Group Limited (ASX:ALC) today releases an updated investor presentation produced for the Canaccord Genuity 43rd Annual Growth Conference. For p
Slide 2: Canaccord Genuity Growth Conference Investor Presentation
For personal use only Canaccord Genuity Growth Conference Investor Presentation KATE QUIRKE MANAGING DIRECTOR & CEO AUGUST 2023
Slide 3: Making the right thing to do, the easiest thing to do
Alcidion helps healthcare organisations harness the power of technology to create a clinically relevant environment with digitally enabled care… For personal use only “Making the right thing to do, the easiest thing to do” 2
Slide 4: Alcidion – a snapshot
Alcidion – a snapshot For personal use only • Healthcare software and informatics company providing an innovative technology platform to improve the efficiency and quality of patient care • Aggregate and analyze data, using AI to enable a proactive (rather than reactive) approach to patient care • 4
Slide 5: Challenges facing healthcare providers
Challenges facing healthcare providers For personal use only Healthcare providers must adopt technology to improve patient outcomes and deliver efficiencies to meet demand Healthcare needs to further extend digital capabilities to increase automation and reduce administrative burden Demographic Indu
Slide 6: Challenges We Seek to Address
Challenges We Seek to Address Designed for Modern Healthcare For personal use only Patient Safety Highly interoperable & built on open standards Clinical Productivity Designed to be an active participant in health care rather than passive data store Patient Flow & Logistics Applies CDS, AI, ML, NLP
Slide 7: Miya Precision
Miya Precision Miya Precision - an For personal use only innovative event driven Tailored clinical decision Responsive to new clinical platform, consolidating support engineering risk information data in open FHIR standard out of healthcare Uses open standards & Creates ecosystem for integrates with
Slide 8: Our Value Proposition against larger incumbents
Our Value Proposition against larger incumbents… For personal use only Incumbents Cloud native • Primarily on premise or data centre deployments Full cloud-first solution – rivals EPR providers in UK • Progressively developing cloud ability but not native Reduces capital costs and increases effi
Slide 9: Miya Precision…making it easier for clinicians
Miya Precision…making it easier for clinicians For personal use only • Device Agnostic – new generation of clinicians comfortable using mobile/tablet • Intuitive dashboards – easy to read while time poor and on the move • Clinical support – assisting clinicians with relevant tests and workflows give
Slide 10: Miya Precision – leveraging AI and NLP
Miya Precision – leveraging AI and NLP For personal use only • Using AI and deeply embedded NLP Miya Precision enables clinical risk detection • Flexible Clinical Decision Support (CDS) such as… • Use CDS to monitor patients in the home for deterioration (remote or virtual care) • Identify critical
Slide 11: Flagship customers validating Alcidion offering
Flagship customers validating Alcidion offering… Customers are very ‘sticky’ with average contact length of 3-5 years with further options to extend; critical enterprise health software For personal use only • US$21M1 TCV2 for Alcidion over 5.5 years South Tees NHS Trust (UK) – TCV for Leidos of US$
Slide 12: Significant Growth Opportunity in UK
Significant Growth Opportunity in UK… For personal use only For Illustrative Purposes Only Government Bodies NHS England + NHSX Alcidion’s Customer (Future, ICS* ICS #1 ICS #2 (42) albeit still emerging) Trusts Alcidion’s Customer (Today) T #1 T #2 T #3 T #4 T #5 T #6 (~146 Acute) • ~40 (27%) NHS Tr
Slide 13: Global expansion potential
Global expansion potential… For personal use only Current Operations Future Geographical Expansion Key Criteria: Australia & New United • Sizable market Zealand Kingdom • English speaking (reduced development spend) • Healthcare structure similar to UK / Australia • Access to digital healthcare data
Slide 14: Our revenue model and breakdown
Our revenue model and breakdown… Licence fees + Maintenance & Support (M&S) recurring revenue underpin sustainable and increasingly profitable growth For personal use only Core Offering Products ~94%1 Technical Services ~6%1 Key Product / Data analytics, Integration, Services interoperability & tech
Slide 15: Our sales strategy: Modular sales driving TCV uplift
Our sales strategy: Modular sales driving TCV uplift Miya Precision’s modular design supports a ‘land & expand’ strategy to support automation and digitalization in healthcare For personal use only *For illustrative purposes only Ability over time to replicate full EPR contract value (US$15m - $30m)
Slide 16: Demonstrating a track record of growth
Demonstrating a track record of growth… For personal use only Revenue (US$M), 30 June Y/E Qtr’ly Cumulative Cash Receipts (US$m) H1 H2 35.0 26.8+ FY21 FY22 FY23 30.0 31.4 23.0 27.8 25.0 17.3 20.0 21.5 19.6 12.5 18.4 15.0 15.0 12.6 10.0 11.0 8.0 5.0 7.2 4.4 4.3 - FY20 FY21 FY22 FY23 Q1 Q2 Q3 Q4 • 94%
Slide 17: Supportive Shareholder base
Supportive Shareholder base For personal use only Snapshot (ASX: ALC) Major Shareholders Shares % Holding Last Traded Price (A$) $0.125 Board & Management (current / former) Shares on Issue (m) 1,268 million Malcolm Pradhan (former co-founder) 134.6m 10.6% Market Capitalisation (US$m)1 $106.2M Raymo
Slide 18: Looking forward…accelerating our momentum
Looking forward…accelerating our momentum For personal use only • US$22.6M1 contracted and renewal revenue to be recognised in FY24 (before new sales) • Strong balance sheet with cash of US$10m and no debt (as of 30 June 2023) • Deep engagement with new and existing customers in relation to further
Slide 19: Disclaimer
Disclaimer For personal use only The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidio
Slide 20: For personal use only
For personal use only 2 > ; U O z
Alcidion Group — Canaccord Genuity 43rd Annual Growth Conference 2023 on 6ix